Latest Breaking News On - Positive topline data - Page 1 : comparemela.com

Horizon Therapeutics plc Reports Second-Quarter 2023 Financial Results

Second-Quarter 2023 Results: Net Sales of $945.0 Million, Representing Year-Over-Year Growth of 11% Excluding Inflammation Medicines GAAP Net Income of $127.1 Million; Adjusted EBITDA of.

United statesTim walbertEuropean congressAmgen incApotex incUnited states federal trade commissionCompanies to workViela bio incTop biotechnology pharmaceutical companyRepresenting year over growthExcluding inflammationNet salesRecent company highlightsPositive topline dataLow clinical activity scoreThyroid eye disease

Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results

First-Quarter 2023 Results: Net Sales of $832.1 Million GAAP Net Income of $54.7 Million; Adjusted EBITDA of $232.9 Million TEPEZZA® Net Sales of $405.3 Million . | May 3, 2023

United statesTim walbertViela bio incCompanies to workTop biotechnology pharmaceutical companyClinical program expected toAmgen incApotex incUnited states federal trade commissionNet salesRecent company highlightsPositive topline dataLow clinical activity scoreThyroid eye diseaseSpecify treatmentDisease activity

Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2022 Financial Results

Fourth-Quarter 2022 Results: Net Sales of $942.0 Million GAAP Net Income of $120.4 Million; Adjusted EBITDA of $357.5 Million; Includes $37.3 Million of Acquired IPR&D and Milestones Expenses

United statesDennis riedlGeoff curtisTim walbertTina venturaRay gordonErin linnihanClinical program expected toAlkem laboratories incAmgen incCorporate affairsApotex incNet salesYear over increaseRecord adjustedOperating cash flow

Horizon Therapeutics plc Reports Third-Quarter 2022 Financial Results; Increases Full-Year 2022 Net Sales and Adjusted EBITDA Guidance; Increases TEPEZZA and KRYSTEXXA Peak Annual Net Sales Expectations

Third-Quarter 2022 Results: Net Sales of $925.4 Million GAAP Net Income of $135.8 Million; Adjusted EBITDA of $335.3 Million, Which Includes $19.0 Million of Acquired IPR&D and Milestones

United statesGeoff curtisTim walbertTina venturaRay gordonErin linnihanCompanies that careShare repurchase programSubcutaneous sc administration trialAmerican college of rheumatologyKey clinical development programsDevelopment for the treatment of autoimmune diseasesResearch in multiple sclerosisClinical programApotex incDivision of corporation

MeiraGTx Reports Second Quarter 2022 Financial and Operational Results

MeiraGTx Reports Second Quarter 2022 Financial and Operational Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesCity ofJason bracoBotaretigene sparoparvovecLifesci communicationsMeiragtx holdingsJanssen pharmaceuticals incAmerican academy of ophthalmologyJanssen pharmaceutical companies of johnsonWall streetPositive topline dataX linked retinitis pigmentosaManufacturing facilities extends cash runwayFourth quarterAlexandria forbes